China Money Network
Login
Join

Decheng Capital Leads $30M Series C Round In China’s Impact Therapeutics

  • August 3, 2018 — 17:26 CST

This Data Is Locked!

This area is available only to Subscribers.

Chinese investment firm Decheng Capital has led a US$30 million series C round in Nanjing-based pharmaceutical firm Impact Therapeutics. Existing investor Lilly Asia Ventures also... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Join

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?

Login
Related Topics:

Related Data: